Re: Amerykanie trawią?

wklejam oryginał tego opisanego wyżej fragmentu zapisu z telekonferencji, bo googlowe tłumaczenie dla wielu z nas pewnie gorsze niż czytanie po angielsku:
And just giving you an idea on cost cutting, and we don't have these exact numbers yet, but we will have them in about 10 days. We've been working on this for a while. If you have a problem where you have a wet tap, in other words, the needle has gone beyond the epidural space and you've now touched the membrane surrounding the spinal column, which keeps the cerebral liquid in that area protecting the spinal column, you now have a puncture. If it just touches that membrane, you have a puncture. So you have the leakage of cerebral liquids, so you have morbidity. The patient then has to remain in the hospital for an average of two days plus, which in the United States is about $3,000 a day. These patients are in for labor and delivery. So there is a new bone involved. So the new bone has to spend two days and additional costs. By law, the -- another anesthesiologist has to do another epidural, it's a course factor to that. Then you have to do an MRI or a CAT scan. It's about $s525. Then there is medicine involved. So this is a very significant problem. And the reason we decided to do the epidural instrument prior to all the other possibilities is this happens not one out of the million, but 4.5% of the time. And then there is litigation, the average in the litigation is approximately $400,000 each time that happens. Patient can have severe migraine headaches up to six weeks, a transient paralysis of up to two years from the point of injection down or permanent paralysis. There is other morbidity as well.
So we believe, given the clinical studies that have been -- that we've had so far and the injections given since our clinical study, which in itself was enormously successful, that we provide the answer to this. We will significantly reduce the morbidity, significantly reduce the cost to the institution and significantly reduce the malpractice . And we are at the point now where we are -- we have demonstrated to leading institutions, and they are evaluating our product at this point. So that's what I think we have to look forward to and I think the next major event for the company rather than quarter-on-quarter movement in the dental business what we -- stockholder should looking for our arrangements with other companies to bring the product worldwide.